04:18 AM EST, 12/30/2024 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said over the weekend it filed a biologics license application with the US Food and Drug Administration for TLX250-CDx for the diagnosis and characterization of clear cell renal cell carcinoma, a form of kidney cancer.

The regulator is expected to advise the target action date under the Prescription Drug User Fee Act for the product following a 60-day administrative review process.